Thomas P Soloway's Net Worth
$12.8 Million
Who is Thomas P Soloway?
Thomas P Soloway has an estimated net worth of $12.8 Million. This is based on reported shares across multiple companies, which include Satsuma Pharmaceuticals, Inc., Transcept Pharmaceuticals Inc, Audentes Therapeutics, Inc., and Third Harmonic Bio, Inc..
SEC CIK
Thomas P Soloway's CIK is 0001454280
Past Insider Trading and Trends
2011 was Thomas P Soloway's most active year for acquiring shares with 5 total transactions. Thomas P Soloway's most active month to acquire stocks was the month of December. 2020 was Thomas P Soloway's most active year for disposing of shares, totalling 8 transactions. Thomas P Soloway's most active month to dispose stocks was the month of December. 2020 saw Thomas P Soloway paying a total of $494,897.26 for 190,888 shares, this is the most they've acquired in one year. In 2020 Thomas P Soloway cashed out on 558,145 shares for a total of $11,003,040.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Satsuma Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Transcept Pharmaceuticals Inc No price found
EVP, Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
$5.01 | -$427,900.28 |
0
|
Scheduled
|
Dec 1
| ||
Form 4
|
—
|
0
|
$5.28 | -$70,516.00 |
0
|
Scheduled
|
Nov 23
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 12
| |||
Form 4
|
∞
| 31.23K |
—
|
—
| 31.23K |
Jan 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Audentes Therapeutics, Inc. No price found
Executive Vice President, CFO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -183.38K |
$60.00 | -$11,003,040.00 |
0
|
Jan 15
| |||
Form 4
| +464.33% | 150.89K |
$3.28 | $494,897.26 | 183.38K |
Jan 8
| |||
Form 4
| +52.46% | 11.18K |
$31.07 | -$1,675,104.00 | 32.5K |
Dec 12
| |||
Form 4
| -2.31% | -505.00 |
$59.21 | -$29,901.05 | 21.31K |
Dec 5
| |||
Form 4
| -2.26% | -505.00 |
$31.02 | -$15,665.10 | 21.82K |
Sep 5
| |||
Form 4
| -4.32% | -1.01K |
$37.31 | -$37,645.79 | 22.32K |
Jun 5
| |||
Form 4
|
∞
| 23.33K |
—
|
—
| 23.33K |
Feb 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Third Harmonic Bio, Inc. (THRD) Snapshot price: $12
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||